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Abstract: Lipid droplets (LDs) serve as energy rich reservoirs and have been associated with
apolipoprotein E (APOE) and neurodegeneration. The E4 allele of APOE (E4) is the strongest genetic
risk factor for the development of late onset Alzheimer’s disease (AD). Since both E4 carriers and
individuals with AD exhibit a state of cerebral lipid dyshomeostasis, we hypothesized that APOE
may play a role in regulating LD metabolism. We found that astrocytes expressing E4 accumulate
significantly more and smaller LDs compared to E3 astrocytes. Accordingly, expression of perilipin-2,
an essential LD protein component, was higher in E4 astrocytes. We then probed fatty acid (FA)
metabolism and found E4 astrocytes to exhibit decreased uptake of palmitate, and decreased oxidation
of exogenously supplied oleate and palmitate. We then measured oxygen consumption rate, and
found E4 astrocytes to consume more oxygen for endogenous FA oxidation and accumulate more
LD-derived metabolites due to incomplete oxidation. Lastly, we found that E4 astrocytes are more
sensitive to carnitine palmitoyltransferase-1 inhibition than E3 astrocytes. These findings offer the
potential for further studies investigating the link between astrocyte lipid storage, utilization, and
neurodegenerative disease as a function of APOE genotype.
Keywords: APOE; astrocytes; lipid droplets; lipid metabolism; AD; PLIN-2; fatty acid oxidation
1. Introduction
Apolipoprotein E (apoE) is associated with circulating lipoproteins, specifically very low-density
lipoproteins and high-density lipoproteins [1]. The polymorphic APOE gene encodes for three
isoforms, E2, E3, and E4, with frequencies of 8%, 77%, and 15%, respectively, in the general US
population [2]. E4 is the strongest genetic risk factor for late onset Alzheimer’s disease (AD) [2].
In addition to established effects on AD neuropathology, APOE genotype is also recognized as a strong
modulator of cerebral metabolism [3–6]. In fact, cognitively normal E4+ individuals demonstrate
alterations in cerebral fatty acid (FA) and carbohydrate metabolism congruent with AD patients [4,7].
Understanding the metabolic effects of apoE in the brain may be a critical step in discovering the
underlying mechanism(s) of E4-driven AD risk.
The brain is one of the largest site of apoE synthesis, second to the liver [8]. The majority of brain
apoE is astrocyte derived, though under certain conditions such as trauma, neurons and microglia also
synthesize apoE [9]. ApoE binds to receptors of the low-density lipoprotein receptor family, which are
expressed on astrocytes as well as neurons [10]. Astrocytes aid in shuttling lipids from the blood-brain
barrier (BBB) to neurons by both binding and internalizing BBB permeable FAs from the endothelial
cells, and loading lipid-free apoE with cargo through action of the ATP-binding cassette transporters
such as ABCA-1 [11,12]. Therefore, astrocytes are key players in the lipid uptake-apoE-lipidation
axis, and are vital to maintaining brain lipid homeostasis and proper neuronal function. Not only
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are astrocytes critical for uptake and export of FAs and lipid-loaded lipoproteins, they also are the
main cell population mediating β-oxidation of FAs in the brain [13,14]. Astrocytes contain a higher
relative density of mitochondria than the surrounding neuropil, giving them superior machinery
to oxidize FA [15]. Furthermore, carnitine palmitoyltransferase-1 (CPT-1), an essential enzyme for
the beta-oxidation of long chain FA, is preferentially expressed in astrocytes compared to neurons,
microglia, and oligodendrocytes [16]. Recent studies clearly show that the brain does in fact utilize a
significant amount of FAs, with some reports estimating FAs are responsible for up to 20% of cerebral
ATP generation [14,17].
Lipid droplets (LD) are organelles containing triacylglycerols and cholesterol esters surrounded
by a layer of amphipathic lipids and associated proteins. Once thought to be inert cellular depots of
fat, lipid droplets are now considered to be dynamic organelles that play a role in various metabolic
diseases [18,19]. Indeed, the overaccumulation of LDs has been linked to atherosclerosis, metabolic
syndrome, cancer, and diabetes [20,21]. However, only recently have studies begun to address the
potential pathological consequences of abnormal LD accumulation in the brain [18]. Although low
amounts of LD are observed in the brain under normal conditions [22], studies have noted increased
LD content in neurodegenerative conditions such as Parkinson’s [23] and AD [24,25]. Interestingly,
Alois Alzheimer noted glial lipid accumulation in his first description of AD pathology [26], but this
has gone relatively unstudied apart from a few reports linking LDs and AD [24,27]. Recent findings
suggest that glial cells within the brain form LD as a function of neuronal stress, and in the fly brain
this process is apoE dependent [27]. Astrocyte derived E4 has been shown to promote LD formation in
fibroblasts [28], and iPSC-derived astrocytes expressing E4 exhibit increased lipid storage in the form
of cholesterol [29]. E4 astrocytes also show varied expression of numerous genes associated with lipid
metabolism and transport, compared to those expressing E3 [29]. However, apoE-isoform specific
modulation of LD accumulation and FA metabolism in astrocytes has not been previously described.
In this study, we characterize an increase in lipid droplet formation and endogenous FA utilization
in E4 astrocytes, as well as decreased uptake and oxidation of exogenous FAs. These lipid metabolism
events influenced by APOE offer both targets for future late onset AD therapies and potential for more
studies analyzing the metabolic effects of APOE in the brain.
2. Materials and Methods
2.1. Cell Culture
E3 and E4 expressing astrocytes were derived from targeted replacement mice expressing human
APOE3 or APOE4 (kind gift from Dr. David Holtzman). These cell lines secrete apoE in high density
lipoprotein-like particles at equivalent levels to primary astrocytes from targeted replacement APOE
knock-in mice and have been relied upon for studies of APOE’s role in astrocyte metabolism by many
groups [30–33]. Cells were maintained in Advanced Dulbecco’s Modified Eagle Medium (DMEM)
(Gibco, Carlsbad, CA, USA) supplemented with 1 mM sodium pyruvate, 1× Geneticin, and 10% fetal
bovine serum. For imaging experiments, cells were grown on sterilized coverslips in 6-well plates
pre-treated with poly-L. For lipid loading experiments, 250 µM oleate pre-conjugated to bovine serum
albumin (BSA) (Sigma, St. Louis, MO, USA) was added to the media 24 h prior for lipid droplet
induction as previously described [34].
2.2. Western Blotting
Cells were lysed on ice using radioimmunoprecipitation assay Buffer (Thermo Fisher Scientific,
Waltham, MA, USA) with 1× proteinase inhibitor (Sigma, St. Louis, MO, USA ). Protein concentration
was determined by Pierce bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Waltham,
MA, USA). 20–30 µg of protein was diluted with 2× Laemmli Sample Buffer (Bio-Rad Laboratories,
Hercules, CA, USA) and heated at 100 ◦C for 10 min. Protein samples were then loaded on
4–20% PROTEAN TGX gels (Bio-Rad Laboratories, Hercules, CA, USA) for SDS-PAGE. Gels were
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transferred using a Trans-Blot Turbo Transfer system (Bio-Rad Laboratories, Hercules, CA, USA) onto
polyvinylidene fluoride membrane. Membranes were then blocked for 2 h in 1% casein and then
incubated overnight in primary antibody solution (1:1000 PLIN-2 (Novus Biologicals, Centennial, CO,
USA); 1:1000 APOE (Abcam Inc., Cambridge, MA, USA); 1:1000 β-actin (Novus)) at 4 ◦C. Membranes
were then washed three times for five minutes each with PBS, pH 7.4, 0.05% Tween-20, and then
incubated with secondary antibody solution (1:10,000 Goat α rabbit IR 680 (LI-COR, Lincoln, NE, USA);
1:5000 goat α mouse IR 800 (LI-COR)) for 2 h at room temperature. Membranes were then washed as
before, with an additional two 10 min washes in PBS. Images were acquired on a LI-COR Odyssey
Infrared Scanner. Resulting images were exported to ImageJ for blot densitometry and quantification.
2.3. Lipid Droplet Imaging
After lipid incubation, coverslips were lifted from the wells and cells were fixed for 15 min in
4% PFA, washed 1× with PBS, and incubated for 30 min in 1:1000 LipidSpot (Biotium, Fremont, CA,
USA). Coverslips were then mounted onto slides using Fluoroshield mounting media with DAPI
(Abcam). Slides were kept at 4 ◦C. Wide field images were obtained on a Nikon Ti2 microscope
using a 20× objective. Single cell images were obtained on a Nikon A1R Laser Scanning Confocal
Microscope (Nikon, Tokyo, Japan) using an oil immersed 100× objective. Astrocytes were selected
in the 405 channel (DAPI-stained nuclei) and then the 610 channel was added (LipidSpot-stained
LDs) and the images were captured. Z-stacks were taken in a range of 10 µM, 40 images per stack.
3-D reconstructions were processed in Imaris 9.2 software using the surfaces module to obtain statistics
for lipid droplets. Experimenter was blind to slide identity and slides were processed in random order
under identical microscope settings.
2.4. Fatty Acid Uptake Assay
Astrocytes were plated at 50,000 cells/well in CytoStar T plates (Perkin Elmer, Waltham, MA,
USA) and allowed to grow to confluency. Media was aspirated, and new glucose free media
supplemented with either 0.5 µCi/mL 14C-palmitate or 14C-oleate (Perkin Elmer) was added to
the wells. Scintillation bead technology in the wells emitted light proportionate to the cellular uptake
of the FA [35]. Radioactivity counts were read on a Microbeta 2 Microplate Counter (Perkin Elmer)
and normalized to protein content in the well using a BCA assay (Thermo Fisher Scientific, Waltham,
MA, USA).
2.5. Fatty Acid Oxidation Assay
Astrocytes were plated in a 24-well plate at 300,000 cells/well and allowed to grow to confluency
for 24 h. Using a previously published protocol [36], cells were then incubated with 0.5 µCi/mL [1-14C]
palmitate or 0.5 µCi/mL [1-14C] oleate for 24 or 3 h. For the pulse experiment (exogenously supplied
FA) radiolabeled FAs were added in nutrient depleted media (Glucose Free DMEM; 5% FBS) for 3 h.
Buffered 14CO2 in the media was then liberated by addition of 1 M hydrochloric acid and captured on
a filter paper disc pre-soaked with 1N sodium hydroxide. For the pulse chase experiment (endogenous
FA), radiolabeled FAs were added in nutrient rich media (25 mM Glucose; 10% FBS) for 24 h, then
aspirated and nutrient depleted media was added to promote oxidation of fatty acid from intracellular
lipid pools. Radioactivity of the filter paper was measured in a Microbeta 2 Microplate Counter after
addition of 3 mL Ultima-Gold Scintillation Fluid. Acid soluble metabolites, which represent incomplete
oxidation of the fatty acids, were extracted from the media and cellular fractions. Total protein from
each well was assayed using a BCA assay (Thermo) and all radioactivity measures were normalized to
protein content.
2.6. Seahorse Extracellular Flux Analysis
Astrocytes expressing E3 or E4 were seeded in a 96-well microplate at 50,000 cells/well and left
to form a monolayer overnight. Media was aspirated and 135 µL of limited nutrient running media
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(DMEM; 5 mM glucose, 2.5 mM carnitine, 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
was added to each well and allowed to incubate for 1 h. Then 30 µL of 1 mM sodium palmitate
complexed to BSA (6:1 molar ratio) or BSA alone was added to wells according to group assignment,
at which point the oxygen consumption rate (OCR) was determined by a Seahorse Extracelluar
Flux Analyzer xF96 (Agilent, Santa Clara, CA). At each successive 18 min, an injection of 200 µM
etomoxir, 1 µM oligomycin, or 1 µM Rotenone | Antimycin was added to each well to inhibit carnitine
palmitoyltransferase-1 (CPT-1), ATP synthetase, or complex I and III respectively. OCR was measured
every 6 min. Values were normalized to protein content in each well by a BCA Assay (Thermo).
OCR from endogenous FA oxidation was determined by calculating the average etomoxir effect in
BSA treated astrocytes (Equation (1)).
OCREndo FAO = OCRPre−Eto Control − OCRPost−Eto Control (1)
OCR from exogenous FA oxidation was determined by calculating the average difference in basal
OCR in the palmitate treated astrocytes versus the basal OCR in BSA treated astrocytes (Equation (2)).
OCRExo FAO = OCRPre−Eto PA − OCRPre−Eto Control (2)
2.7. Statistical Analysis
All data are expressed as mean ± standard error. Comparisons between two groups were
analyzed by t-test. Multiple groups and/or multiple time points were analyzed using ANOVAs (Prism,
Graphpad, San Diego, CA, USA), or repeated measures ANOVA (time × groups) (SPSS). Statistical
significance was determined using an error probability level of p < 0.05 corrected by a false discovery
rate (FDR) analysis (Benjamini Hochberg method).
3. Results
3.1. E4 Astrocytes Increased LD Count, Increased Cellular LD Volume, Decreased LD Size
We first asked if APOE influences lipid storage within astrocytes. To answer this, we lipid-loaded
E3 and E4 astrocytes with 250 µM oleate for 24 h, stained for neutral LDs (Figure 1A and Figure S3A),
and quantified LDs per cell (Figure 1B and Figure S3B). E4 astrocytes showed a significant increase in
the number of LDs, both at basal levels and in a FA-rich environment, compared to E3. (Figure 1B) Total
LD volumes within the cell were also analyzed, and E4 astrocytes held significantly more lipid volume
under lipid loaded conditions compared to E3. (Figure 1C). Furthermore, expression of perilipin-2
(PLIN-2), a LD associated protein, was increased in E4 astrocytes in an FA-rich environment compared
to E3. (Figure 1D,E and Figure S1).
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quantified. Values represented are means +/− SEM (n = 10). Data were analyzed by t-test for specific 
comparisons between means; * p < 0.05. (D) Representiative image of the total expression of perilipin-
2 (PLIN2) and β-actin in control or lipid-loaded E3 and E4 astrocytes was determined by SDS-PAGE 
and Western blotting and quantified (E). Values represent mean +/− SEM (n = 3). Data were analyzed 
by by t-test; * p < 0.05. Scale bar = 100µm. 
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2B–D) and binned using 0.1 µm as a bin size. It was found that E4 astrocyte LDs were on average 
54.8% smaller on a volume per droplet basis than E3s under control conditions, and 33.7% smaller 
when lipid-loaded. Together, these results suggest that E4 astrocytes form more LDs than E3 
astrocytes regardless of FA exposure, as reflected in increased expression of PLIN-2 and an increased 
LD count.  
Figure 1. E4 astrocytes have increased lipid droplet (LD) count, LD volume, and LD associated
protein. (A) Astrocytes expressing either E3 or E4 were stained with LipidSpot to quantify lipid conten
under co trol conditions (left), and after 24 h oleic acid (OA) suppl mentation (“li id-loaded”; right).
The number of LDs pe indivi ual cell (B) and total LD volume per cell (C) were quantified. Values
represented are means +/− SEM (n = 10). Data were analyzed by t-test for specific comparisons
between m ans; * p < 0.05. (D) Representi tive image of the total expression of perilipin-2 (PLIN2) and
β-actin in control or lipid-loaded E3 and E4 astrocyt s was determined by SDS-PAGE and Western
blotting and quantified (E). Values represent mean +/− SEM (n = 3). Data wer analyz by t-test;
* p < 0.05. Scale ar = 100 µm.
To determine LD size and distribution, LDs in individual cells were rendered using Imaris software
under control and lipid-loaded conditions (Figure 2A), and volumes were quantified (Figure 2B–D)
and binned using 0.1 µm as a bin size. It was found that E4 astrocyte LDs were on average 54.8%
smaller on a volume per droplet basis than E3s under control conditions, and 33.7% smaller when
lipid-loaded. Together, these results suggest that E4 astrocytes form more LDs than E3 astrocytes
regardless of FA exposure, as reflected in increased expression of PLIN-2 and an increased LD count.
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(Figure 3A–B), with no significant difference in oleate uptake (Figure 3C). Conversely, there was a 
trend toward increased oleate uptake in E4 astrocytes, with cumulative uptake slightly higher when 
expressed as the area under curve despite lacking statistical significance. (Figure 3D) These data 
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Figure 2. E4 astrocytes have smaller lipid droplets. (A) Representative 3D renderings of E3 and E4
astrocytes stained with LipidSpot nd DAPI under control and lipid-load d conditions. (B) Individual
lipid droplet (LD) volume was quantified under control and ipi - oaded conditi s. Values represented
are means +/− SEM. Data were analyzed by unpaired t-test; *** p < 0.001, * p < 0.05. (C) Relative
frequ ncies of LD volumes were binned between 0 and 1 µm3 under control and (D) lipid loaded
conditions. Bin size = 0.1 µm3. E3 control LDs (n = 131); E4 control LDs (n = 775); E3 OA LDs (n = 231);
E4 OA LDs (n = 1208).
3.2. E4 Astrocytes Take Up Less Palmitate
Hypothesizing that an increase in lipid storage may be a result of increased uptake of FAs, we
next sought to determine if APOE regulates astrocyte FA uptake. Using a scintillation proximity
assay and treating with 14C-labeled FAs, we found E4 astrocytes to take up significantly less palmitate
(Figure 3A,B), with no significant difference in oleate uptake (Figure 3C). Conversely, there was a
trend toward increased oleate uptake in E4 astrocytes, with cumulative uptake slightly higher when
expressed as the area under curve despite lacking statistical significance. (Figure 3D) These data
suggest that APOE isoforms may modulate FA uptake in astrocytes dependent on the FA species.
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Figure 3. E4 astrocytes uptake less palmitate, but not oleate. E3 and E4 astrocytes were treated with 0.5
µCi/mL [1-14C] palmitate (A,B) or (C) [1-14C] olea e (C,D) and uptake was measured over 150 min
by a scintillation proximity assay. Values represent mean +/− SEM (n = 6). Data were analyzed by
two-way ANOVA of repeated measures (A,C) or t-test (B,D); * p < 0.05. Total area under the curve
(AUC) was determined for palmitate (B) and oleate (D).
3.3. E4 Astrocytes Oxidize Less Exogenous Fatty Acids
We next examined how APOE might regulate FA oxidation in astrocytes. We first assessed how
E3 and E4 astrocytes oxidize exogenously supplied FA. We treated cells with radiolabeled palmitate
or oleate for 3 h in a nutrient depleted media, and captured the oxidation product CO2, as well as
incompletely oxidized products of FA metabolism in the form of acid soluble metabolites (ASM).
(Figure 4A). We found that E4 astrocytes oxi ize significantly less exogenously supplied oleate and
palmitate than E3 astrocytes (Figure instead accumulate s gnificantly more metabolites that
are cid soluble (Figure 4C,D); these l de ketone bodies, acyl car itines, citric acid cycle
intermediates, and FA less than six carbons in length [36]. We found an increased concentration of
these ASM inside E4 cells (Figure 4C). We also found an increased concentration of ASM in the media
(Figure 4D), suggesting that E4 astrocytes may export more FA metabolites than E3s. Using Seahorse
Extracellular Flux Analysis, we then measured the oxygen consumption rate (OCR) before and after
inhibition of CPT-1 in E3 and E4 astrocytes supplied with palmitate in the media (Figure 4E). We found
E4 astrocytes to exhibit a lower OCR compared to E3 at all time points (Figure 4E). This lower OCR
is likely primarily d e to a decreased rate of glucose oxidation, as E4 is strongly associated with a
phenotype of glucose h p etabolism [4,37]. When we specifically calculated the contribution of
FA oxidation to OCR by comparing basal OCR in palmitate treated versus BSA treated astrocytes,
we found that E4 astrocytes utilize significantly less exogenously supplied FA as part of their basal
respiration (Figure 4F).
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Figure 4. E4 astrocytes oxidize less exogenously supplied fatty acids. (A) Schematic and summary of
pulse experiment to determine oxidation of exogenously supplied fatty acids. (B) E3 and E4 astrocytes
were treated with [1-14C] oleate (OA) or [1-14C] palmitate (PA) and oxidation was measured over
3 h by a CO2 trap assay. Acid soluble metabolites were quantified in media (C) and intracellular
(D) fractions. Values represent mean +/− SEM (n = 6). Data were analyzed by t-test;*** p < 0.001,
**** p < 0.0001. (E) E3 and E4 astrocytes were pretreated for 1 h with palmitate and subjected to a
Seahorse Extracellular Flux Fatty Acid Oxidation Assay. Vertical gray dashes indicate time points of
pharmacological injections of etomoxir (Eto), oligo ycin (Oligo), or Rotenone and Antimycin (RA).
(F) Oxygen co sumption due to F i ation of exogenou ly supplied palmitate was determined
(see met and graphed. Valu s represent means +/− SEM (n = 3–4). D ta were a alyzed by
unpaired t-test; * p < 0.05.
Since E4 astrocytes showed a significant i creas in LD accum lation, we n xt studied how APOE
modulates FA oxidation from intracellular FA pools. Knowi g that incubation with oleate for 24 h
induces LD formation, we “pulsed” E3 and E4 astrocytes with radiolabeled FAs for 24 h to incorporate
the radiolabel into LDs (Figure 5A). We then aspirated the media, washed with PBS, and captured
oxidation and non-oxidation products of the intracellular FAs after a 4 h “chase”. Interestingly, in
contrast to the oxidation of exogenously supplied FA, E3 and E4 astrocytes showed no difference in
CO2 production from intracellular pools of oleate or palimate (Figure 5B). Quantification of ASMs of
intracellular palmitate and oleate revealed that E4 astrocytes once again exported significantly more
ASM into the media (Figure 5C), and have similar levels within the cells (Figure 5D). We next quantified
OCR using Seahorse in E3 and E4 astrocytes that were incubated in serum free media and not supplied
with exogenous FA (Figure 5E), assuming the only source of FA would be from intracellular LDs.
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We found that the OCR in E4 astrocytes that could be attributed to oxidation of endogenous FA was
significantly higher than E3 astrocytes, suggesting that while CO2 production is similar between
genotypes, E4 astrocytes seem to consume more oxygen from the metabolism of intracellular FAs
(Figure 5F). Together these data suggest that APOE alters FA oxidation in astrocytes, and that these
effects differ depending on the source of FAs (endogenously stored as LD vs exogenously supplied
in media).
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Figure 5. E4 astrocytes oxidize re endogenous fatty acids. (A) Schematic and time-course of
pulse-chase experiment to determine oxidation of endogenous fatty acids.. (B) E3 and E4 astrocytes
were treate it 1 i L [1-14C] oleate (OA) or [1-14C] palmitate (PA) combined with non-labelled
isotopes to 200 µM in Advanced DMEM for 24 h, washed with PBS, and then oxidation was measured
over 4 h in a nutrient depleted media by a CO2 trap assay. Acid soluble metabolites were quantified
in media (C) and intracellular (D) fractions. Values represent mean +/− SEM (n = 6). Data were
analyzed by t-test; ** p < 0.01, *** p < 0.001; **** p < 0.0001. (E) E3 and E4 astrocytes were pretreated for
1 h with bovine serum albumin supplemented media and subjected to a Seahorse Extracellular Flux
Fatty Acid Oxidation Assay. Vertical gray dashes indicate time points of pharmacological injections of
etomoxir (Eto), oligomycin (Oligo), or Rotenone and Antimycin (RA). (F) Oxygen consumption due to
intracellular FA oxidation was determined (see methods) Results were normalized to protein content.
Values represent means +/− SEM (n = 3–4). Data were analyzed by unpaired t-test; *** p < 0.0005.
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3.4. E4 Astrocytes Are More Sensitive to CPT-1 Inhibition
Since CPT-1 is the rate-limiting enzyme of fatty acid oxidation, we hypothesized that E3 and E4
astrocytes may exhibit varying responsiveness to CPT-1 inhibition. Using Seahorse, we measured OCR
before and after CPT-1 inhibition with etomoxir and assessed the percent change in OCR from baseline
in E3 and E4 astrocytes pretreated with palmitate and the non-pretreated control cells (Figure 6A).
We found that E4 astrocytes have a significantly larger drop in OCR after CPT-1 inhibition compared
to E3 astrocytes in both pretreated and control cells, suggesting an increased reliance on FA oxidation
for overall OCR (Figure 6A).
To determine if CPT-1 inhibition results in APOE genotype specific effects on palmitate and oleate
oxidation, we used a 14CO2 trap approach and found E4 astrocytes to exhibit a greater fold change
in oxidation of palmitate from the baseline after CPT-1 inhibition (Figure 6B). However, we saw no
differences between genotypes with regards to the etomoxir effect on oleate oxidation (Figure 6B),
again suggesting these APOE effects may be specific to certain FA species.
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4. Discussion
Lipid droplets in astrocytes serve to both sequester fatty acids that would otherwise be cytotoxic if
free in the cytoplasm and to offer an energy rich and accessible pool for cellular metabolic needs in times
of starvation and stress. Recent studies of AD brain tissue have demonstrated an increase in LDs [24,25].
ApoE is an important component of peripheral and central nervous system lipoproteins, which share
many biochemical features with LDs [19]. The E4 allele of APOE is a critical genetic risk factor
for late onset AD, and is strongly associated with a number of metabolic abnormalities [4,29,38,39].
However, the link between E4 and LD biology has not been widely explored. In the current study,
we characterized a number of apoE isoform specific differences in LD formation and FA utilization
in astrocytes.
We found that E4 astrocytes form many small LDs compared to the few large LDs observed in
E3 astrocytes. The structural makeup of LDs could be a contributor to overall LD size. Surfactant
lipids such as phosphotidylcholine (PC) are known to stabilize LD emulsions, while more fusogenic
lipids, such as phosphatidic acid, promote LD coalescence [19,40]. Our group previously showed that
E4 mice brains differ in various lipid concentrations using an unbiased metabolomics approach [41].
Interestingly, Heinsinger et al. recently showed that the apoE isoforms are associated with varying
sizes of CNS lipoproteins, with E4 individuals and astrocytes synthesizing smaller apoE-associated
lipoprotein particles [42]. As the structure and makeup of LDs and lipoproteins are similar, it is
possible that E4 promotes smaller spherical lipid carriers whether that be inside or outside the cell.
Overall isoform specific effects on FA metabolism could also be a result of differing total concentrations
of apoE. E4 astrocytes are known to secrete less apoE into the media and have less intracellular apoE
(Figure S2) [33], and E4 brains from targeted replacement mice have less apoE [43]. Whether the lower
quantity of apoE4 in E4 carriers is related to disease pathogenesis is unknown.
LD associated proteins, such as perilipins, serve to stabilize the LD from excessive lipolysis.
Loss of perilipin-2 has been associated with an increase in endogenous fatty acid oxidation [44].
We found that E4 astrocytes exhibit increased expression of perilipin-2, decreased exogenous FA
oxidation, and increased oxygen consumption from endogenous fatty acid oxidation. Overexpression
of PLIN2 has been liked to a decrease in glucose uptake by LD sequestration of key regulators of
glucose transporters [45]. In unpublished work, our group found that E4 down-regulates astrocyte
glucose metabolism, much like the effects reported in neuronal models of apoE overexpression [38].
It may be that the energetic needs of an E4 astrocyte in the absence of robust glucose metabolism
overpower the inhibitory effect of PLIN2 on LD lipolysis. The overexpression of PLIN2 has also been
shown to increase LD formation in various cell types [46–48]. This is congruent with our findings in
regards to E4 astrocytes, where an increase in LD number paralleled with increased PLIN2 expression.
In hepatocytes, increased levels of reactive oxygen species (ROS) prompt increased PLIN2 expression
subsequent LD formation [46]. ROS has been linked to LDs in glia in a Drosophila model as well,
and this process was found to be apoE dependent [27,49]. Oxidative stress as an inducer of LDs
in astrocytes as a function of APOE deserves further investigation in light of the poor anti-oxidant
capacity of E4 [50]. Alternatively, the presence of many small droplets as opposed to larger droplets
could be a result of increased FA oxidation resulting from LD turnover. More studies are needed in
CNS in vitro models to define LD metabolism and how it may differ from peripheral LD metabolism.
E4 carriage in humans seems to promote an “accelerated AD” status, particularly in terms
of cerebral glucose metabolism [4]. Namely, as individuals transition through mild cognitive
impairment to AD, glucose metabolism progressively decreases in several distinct brain regions [51,52].
E4 individuals, however, show a state of glucose hypometabolism in these same regions even in
the absence of cognitive impairment, and as early as the third decade of life [7]. LDs are known to
increase in cerebral density with age and are found in GFAP+ cells [53]. E4 carriers show an accelerated
development of AD neuropathology and cognitive symptoms, and astrocytes have been shown to play
a key role in E4-driven AD pathogenesis [54]. Perhaps this accelerated AD phenotype in E4 individuals
extends to cerebral LD accumulation as well.
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It has been proposed that E4 carriers may be at risk for cognitive decline because of an E4-driven
disruption in FA metabolism [55,56]. Here we showed that APOE regulates fatty acid metabolism in
the astrocyte depending on the saturation status of the fatty acid. We observed marked decrease in
uptake of the fully saturated fatty acid palmitate in E4 astrocytes compared to E3 astrocytes while no
difference was observed in oleate uptake. When we treated with etomoxir, we saw drastic reduction in
oleate oxidation in both genotypes, but much less of a reduction in oxidation in E3 astrocyte palmitate
oxidation compared to E4. These data may shed light on a phenomenon seen in epidemiological
studies where E4 carriers respond well to an acute high fat meal (by cognitive measures and plasma
AD biomarkers), while non-E4 carriers responded poorly [57]. This may be due to a lower uptake
of saturated fatty acids. Conversely, E4 carriers have been shown to exhibit increased uptake of
unsaturated fatty acids, specifically docosahexaenoic acid [58]. This could be related to the preventative
effect of a Nordic diet rich in fish, fruits, and vegetables on cognitive decline in E4 individuals [59].
Indeed, apoE isoform specific effects on lipid usage have been characterized systemically, wherein
E4 mice show a metabolic preference for oxidizing FAs [60]. Related FA disturbances have been
characterized in humans carrying E4. For instance, E4 carriers show greater uptake, brain incorporation,
and whole-body β-oxidation of docosahexaenoic acid compared to non-E4 carriers [58,61]. In the
current study, our data using 14C-labeled FAs support the idea that E4 alters the flux of metabolites
into the TCA cycle and because of this, decreases CO2 production and increases metabolites that are
acid soluble. Our group previously showed that E4 alters numerous pathways within the cerebral
metabolome [41], and others have shown changes in TCA specific metabolites in the brain [62].
5. Conclusions
In this study we showed that E4 astrocytes display an increase in LD formation compared to E3
astrocytes. Specifically, E4 astrocytes have a higher number of smaller LD and increased expression
of the LD marker PLIN2. We also observed increased oxygen consumption rates from endogenous
fatty acid oxidation, decreased rates of exogenous fatty acid oxidation, and an increased sensitivity to
CPT-1 inhibition in E4, compared to E3, astrocytes. While a number of important questions remain, we
hope these initial findings will serve as a basis for the further study of APOE-associated alterations in
astrocyte metabolism and future treatments of AD and other neurodegenerative diseases.
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